MedTrace Logo

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00884234 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-08-28

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of 2 sequential doses of RT001 compared to vehicle control following applications at Baseline (Day 0) and Week 2.

Conditions

  • Lateral Canthal Lines

Interventions

OTHER

Vehicle Control

Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2

DRUG

RT001 (Botulinum Toxin Type A Topical Gel)

Two sequential doses of RT001 at Baseline (Day 0) and Week 2

Sponsors & Collaborators

  • Revance Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Suzanne Bruce, MD · The Center for Skin Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-04-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00884234 on ClinicalTrials.gov